fexofenadine	ketoconazole	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		none	none	none	none
fexofenadine	ketoconazole	4	4	false	none	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		none	none	none	none
fexofenadine	ketoconazole	4	6	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
fexofenadine	ketoconazole	6	4	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
fexofenadine	ketoconazole	6	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
fexofenadine	ketoconazole	6	7	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
fexofenadine	ketoconazole	6	8	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
fexofenadine	ketoconazole	7	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
fexofenadine	ketoconazole	7	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
fexofenadine	ketoconazole	7	8	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
fexofenadine	ketoconazole	7	9	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
fexofenadine	ketoconazole	8	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
fexofenadine	ketoconazole	8	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
fexofenadine	ketoconazole	8	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
fexofenadine	ketoconazole	8	9	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
fexofenadine	ketoconazole	9	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
fexofenadine	ketoconazole	9	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
fexofenadine	ketoconazole	9	9	false	none	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
fexofenadine	ketoconazole	12	12	true	positive	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  		none	none	none	none
fexofenadine	ketoconazole	12	14	true	positive	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
fexofenadine	ketoconazole	13	12	true	positive	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  		none	none	none	none
fexofenadine	ketoconazole	13	14	true	positive	This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
fexofenadine	ketoconazole	14	12	true	positive	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
fexofenadine	ketoconazole	14	14	true	positive	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
fexofenadine	ketoconazole	15	14	true	positive	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  		none	none	none	none
fexofenadine	Maalox	1	2	false	none	7 DRUG INTERACTIONS    7.1 Antacids    Fexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids.  In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  		none	none	none	none
fexofenadine	Maalox	1	3	false	none	7 DRUG INTERACTIONS    7.1 Antacids    Fexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids.  In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  		none	none	none	none
fexofenadine	Maalox	2	2	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  		none	none	none	none
fexofenadine	Maalox	2	3	false	none	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  		none	none	none	none
fexofenadine	Maalox	4	2	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		none	none	none	none
fexofenadine	Maalox	4	3	false	none	1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		none	none	none	none
fexofenadine	grapefruit	13	15	false	none	This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  		none	none	none	none
fexofenadine	grapefruit	14	15	false	none	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  		none	none	none	none
fexofenadine	grapefruit	15	17	false	none	7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		none	none	none	none
fexofenadine	grapefruit	15	15	false	none	7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  		none	none	none	none
fexofenadine	grapefruit	17	17	false	none	The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		none	none	none	none
fexofenadine	grapefruit	17	15	false	none	7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		none	none	none	none
fexofenadine	grapefruit	21	20	false	none	In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%.  Therefore, to maximize the effects of fexofenadine, it is recommended that fexofenadine hydrochloride tablets should be taken with water [see Clinical Pharmacology (12.3) and Dosage and Administration (2.1)].  		none	none	none	none
fexofenadine	grapefruit	20	20	false	none	In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%.  		none	none	none	none
fexofenadine	Erythromycin	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		none	none	none	none
fexofenadine	Erythromycin	4	4	false	none	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		none	none	none	none
fexofenadine	Erythromycin	4	6	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
fexofenadine	Erythromycin	6	4	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
fexofenadine	Erythromycin	6	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
fexofenadine	Erythromycin	6	7	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
fexofenadine	Erythromycin	6	8	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
fexofenadine	Erythromycin	7	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
fexofenadine	Erythromycin	7	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
fexofenadine	Erythromycin	7	8	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
fexofenadine	Erythromycin	7	9	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
fexofenadine	Erythromycin	8	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
fexofenadine	Erythromycin	8	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
fexofenadine	Erythromycin	8	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
fexofenadine	Erythromycin	8	9	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
fexofenadine	Erythromycin	9	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
fexofenadine	Erythromycin	9	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
fexofenadine	Erythromycin	9	9	false	none	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
fexofenadine	Erythromycin	12	12	true	positive	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  		none	none	none	none
fexofenadine	Erythromycin	12	14	true	positive	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
fexofenadine	Erythromycin	13	12	true	positive	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  		none	none	none	none
fexofenadine	Erythromycin	13	14	true	positive	This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
fexofenadine	Erythromycin	14	12	true	positive	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
fexofenadine	Erythromycin	14	14	true	positive	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
fexofenadine	Erythromycin	15	14	true	positive	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  		none	none	none	none
fexofenadine	Ketoconazole	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		none	none	none	none
fexofenadine	Ketoconazole	4	4	false	none	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		none	none	none	none
fexofenadine	Ketoconazole	4	6	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
fexofenadine	Ketoconazole	6	4	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
fexofenadine	Ketoconazole	6	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
fexofenadine	Ketoconazole	6	7	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
fexofenadine	Ketoconazole	6	8	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
fexofenadine	Ketoconazole	7	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
fexofenadine	Ketoconazole	7	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
fexofenadine	Ketoconazole	7	8	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
fexofenadine	Ketoconazole	7	9	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
fexofenadine	Ketoconazole	8	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
fexofenadine	Ketoconazole	8	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
fexofenadine	Ketoconazole	8	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
fexofenadine	Ketoconazole	8	9	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
fexofenadine	Ketoconazole	9	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
fexofenadine	Ketoconazole	9	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
fexofenadine	Ketoconazole	9	9	false	none	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
fexofenadine	Ketoconazole	12	12	true	positive	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  		none	none	none	none
fexofenadine	Ketoconazole	12	14	true	positive	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
fexofenadine	Ketoconazole	13	12	true	positive	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  		none	none	none	none
fexofenadine	Ketoconazole	13	14	true	positive	This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
fexofenadine	Ketoconazole	14	12	true	positive	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
fexofenadine	Ketoconazole	14	14	true	positive	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
fexofenadine	Ketoconazole	15	14	true	positive	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  		none	none	none	none
fexofenadine	orange	13	15	false	none	This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  		none	none	none	none
fexofenadine	orange	14	15	false	none	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  		none	none	none	none
fexofenadine	orange	15	17	false	none	7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		none	none	none	none
fexofenadine	orange	15	15	false	none	7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  		none	none	none	none
fexofenadine	orange	17	17	false	none	The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		none	none	none	none
fexofenadine	orange	17	15	false	none	7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		none	none	none	none
fexofenadine	orange	21	20	false	none	In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%.  Therefore, to maximize the effects of fexofenadine, it is recommended that fexofenadine hydrochloride tablets should be taken with water [see Clinical Pharmacology (12.3) and Dosage and Administration (2.1)].  		none	none	none	none
fexofenadine	orange	20	20	false	none	In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%.  		none	none	none	none
fexofenadine	histamine	14	16	false	none	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  		none	none	none	none
fexofenadine	histamine	15	16	false	none	7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  		none	none	none	none
fexofenadine	histamine	17	16	false	none	This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		none	none	none	none
fexofenadine	erythromycin	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		none	none	none	none
fexofenadine	erythromycin	4	4	false	none	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		none	none	none	none
fexofenadine	erythromycin	4	6	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
fexofenadine	erythromycin	6	4	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
fexofenadine	erythromycin	6	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
fexofenadine	erythromycin	6	7	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
fexofenadine	erythromycin	6	8	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
fexofenadine	erythromycin	7	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
fexofenadine	erythromycin	7	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
fexofenadine	erythromycin	7	8	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
fexofenadine	erythromycin	7	9	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
fexofenadine	erythromycin	8	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
fexofenadine	erythromycin	8	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
fexofenadine	erythromycin	8	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
fexofenadine	erythromycin	8	9	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
fexofenadine	erythromycin	9	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
fexofenadine	erythromycin	9	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
fexofenadine	erythromycin	9	9	false	none	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
fexofenadine	erythromycin	12	12	true	positive	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  		none	none	none	none
fexofenadine	erythromycin	12	14	true	positive	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
fexofenadine	erythromycin	13	12	true	positive	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  		none	none	none	none
fexofenadine	erythromycin	13	14	true	positive	This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
fexofenadine	erythromycin	14	12	true	positive	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
fexofenadine	erythromycin	14	14	true	positive	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
fexofenadine	erythromycin	15	14	true	positive	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  		none	none	none	none
Fexofenadine hydrochloride	ketoconazole	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		87636	none	236474	none
Fexofenadine hydrochloride	ketoconazole	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		87636	none	236474	none
Fexofenadine hydrochloride	ketoconazole	6	4	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
Fexofenadine hydrochloride	ketoconazole	6	4	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
Fexofenadine hydrochloride	ketoconazole	6	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
Fexofenadine hydrochloride	ketoconazole	6	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
Fexofenadine hydrochloride	ketoconazole	6	7	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	ketoconazole	6	7	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	ketoconazole	6	8	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	ketoconazole	6	8	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	ketoconazole	8	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	ketoconazole	8	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	ketoconazole	8	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	ketoconazole	8	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	ketoconazole	8	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	ketoconazole	8	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	ketoconazole	8	9	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	ketoconazole	8	9	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	ketoconazole	9	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	ketoconazole	9	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	ketoconazole	9	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	ketoconazole	9	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	ketoconazole	9	9	false	none	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	ketoconazole	9	9	false	none	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	17	15	false	none	7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	17	15	false	none	7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	17	17	false	none	The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	17	17	false	none	The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	1	1	false	none	7 DRUG INTERACTIONS    7.1 Antacids    Fexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids.  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	1	1	false	none	7 DRUG INTERACTIONS    7.1 Antacids    Fexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids.  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	1	2	false	none	7 DRUG INTERACTIONS    7.1 Antacids    Fexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids.  In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	1	2	false	none	7 DRUG INTERACTIONS    7.1 Antacids    Fexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids.  In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	2	1	false	none	7 DRUG INTERACTIONS    7.1 Antacids    Fexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids.  In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	2	1	false	none	7 DRUG INTERACTIONS    7.1 Antacids    Fexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids.  In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	2	2	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	2	2	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	21	21	false	none	Therefore, to maximize the effects of fexofenadine, it is recommended that fexofenadine hydrochloride tablets should be taken with water [see Clinical Pharmacology (12.3) and Dosage and Administration (2.1)].  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	21	21	false	none	Therefore, to maximize the effects of fexofenadine, it is recommended that fexofenadine hydrochloride tablets should be taken with water [see Clinical Pharmacology (12.3) and Dosage and Administration (2.1)].  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	21	20	false	none	In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%.  Therefore, to maximize the effects of fexofenadine, it is recommended that fexofenadine hydrochloride tablets should be taken with water [see Clinical Pharmacology (12.3) and Dosage and Administration (2.1)].  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	21	20	false	none	In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%.  Therefore, to maximize the effects of fexofenadine, it is recommended that fexofenadine hydrochloride tablets should be taken with water [see Clinical Pharmacology (12.3) and Dosage and Administration (2.1)].  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	6	4	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	6	4	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	6	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	6	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	6	7	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	6	7	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	6	8	true	negative	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	6	8	true	negative	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	8	6	true	negative	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	8	6	true	negative	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	8	7	true	negative	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	8	7	true	negative	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	8	8	true	negative	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	8	8	true	negative	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	8	9	true	negative	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	8	9	true	negative	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	9	7	true	negative	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	9	7	true	negative	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	9	8	true	negative	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	9	8	true	negative	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	9	9	false	none	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	Fexofenadine	9	9	false	none	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	Maalox	1	2	false	none	7 DRUG INTERACTIONS    7.1 Antacids    Fexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids.  In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  		87636	none	236474	none
Fexofenadine hydrochloride	Maalox	1	2	false	none	7 DRUG INTERACTIONS    7.1 Antacids    Fexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids.  In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  		87636	none	236474	none
Fexofenadine hydrochloride	Maalox	1	3	false	none	7 DRUG INTERACTIONS    7.1 Antacids    Fexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids.  In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  		87636	none	236474	none
Fexofenadine hydrochloride	Maalox	1	3	false	none	7 DRUG INTERACTIONS    7.1 Antacids    Fexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids.  In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  		87636	none	236474	none
Fexofenadine hydrochloride	Maalox	2	2	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  		87636	none	236474	none
Fexofenadine hydrochloride	Maalox	2	2	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  		87636	none	236474	none
Fexofenadine hydrochloride	Maalox	2	3	false	none	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  		87636	none	236474	none
Fexofenadine hydrochloride	Maalox	2	3	false	none	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  		87636	none	236474	none
Fexofenadine hydrochloride	grapefruit	17	17	false	none	The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		87636	none	236474	none
Fexofenadine hydrochloride	grapefruit	17	17	false	none	The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		87636	none	236474	none
Fexofenadine hydrochloride	grapefruit	17	15	false	none	7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		87636	none	236474	none
Fexofenadine hydrochloride	grapefruit	17	15	false	none	7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		87636	none	236474	none
Fexofenadine hydrochloride	grapefruit	21	20	false	none	In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%.  Therefore, to maximize the effects of fexofenadine, it is recommended that fexofenadine hydrochloride tablets should be taken with water [see Clinical Pharmacology (12.3) and Dosage and Administration (2.1)].  		87636	none	236474	none
Fexofenadine hydrochloride	grapefruit	21	20	false	none	In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%.  Therefore, to maximize the effects of fexofenadine, it is recommended that fexofenadine hydrochloride tablets should be taken with water [see Clinical Pharmacology (12.3) and Dosage and Administration (2.1)].  		87636	none	236474	none
Fexofenadine hydrochloride	Erythromycin	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		87636	none	236474	none
Fexofenadine hydrochloride	Erythromycin	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		87636	none	236474	none
Fexofenadine hydrochloride	Erythromycin	6	4	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
Fexofenadine hydrochloride	Erythromycin	6	4	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
Fexofenadine hydrochloride	Erythromycin	6	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
Fexofenadine hydrochloride	Erythromycin	6	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
Fexofenadine hydrochloride	Erythromycin	6	7	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	Erythromycin	6	7	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	Erythromycin	6	8	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	Erythromycin	6	8	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	Erythromycin	8	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	Erythromycin	8	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	Erythromycin	8	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	Erythromycin	8	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	Erythromycin	8	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	Erythromycin	8	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	Erythromycin	8	9	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	Erythromycin	8	9	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	Erythromycin	9	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	Erythromycin	9	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	Erythromycin	9	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	Erythromycin	9	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	Erythromycin	9	9	false	none	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	Erythromycin	9	9	false	none	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	Ketoconazole	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		87636	none	236474	none
Fexofenadine hydrochloride	Ketoconazole	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		87636	none	236474	none
Fexofenadine hydrochloride	Ketoconazole	6	4	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
Fexofenadine hydrochloride	Ketoconazole	6	4	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
Fexofenadine hydrochloride	Ketoconazole	6	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
Fexofenadine hydrochloride	Ketoconazole	6	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
Fexofenadine hydrochloride	Ketoconazole	6	7	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	Ketoconazole	6	7	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	Ketoconazole	6	8	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	Ketoconazole	6	8	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	Ketoconazole	8	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	Ketoconazole	8	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	Ketoconazole	8	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	Ketoconazole	8	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	Ketoconazole	8	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	Ketoconazole	8	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	Ketoconazole	8	9	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	Ketoconazole	8	9	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	Ketoconazole	9	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	Ketoconazole	9	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	Ketoconazole	9	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	Ketoconazole	9	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	Ketoconazole	9	9	false	none	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	Ketoconazole	9	9	false	none	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	orange	17	17	false	none	The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		87636	none	236474	none
Fexofenadine hydrochloride	orange	17	17	false	none	The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		87636	none	236474	none
Fexofenadine hydrochloride	orange	17	15	false	none	7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		87636	none	236474	none
Fexofenadine hydrochloride	orange	17	15	false	none	7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		87636	none	236474	none
Fexofenadine hydrochloride	orange	21	20	false	none	In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%.  Therefore, to maximize the effects of fexofenadine, it is recommended that fexofenadine hydrochloride tablets should be taken with water [see Clinical Pharmacology (12.3) and Dosage and Administration (2.1)].  		87636	none	236474	none
Fexofenadine hydrochloride	orange	21	20	false	none	In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%.  Therefore, to maximize the effects of fexofenadine, it is recommended that fexofenadine hydrochloride tablets should be taken with water [see Clinical Pharmacology (12.3) and Dosage and Administration (2.1)].  		87636	none	236474	none
Fexofenadine hydrochloride	histamine	17	16	false	none	This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		87636	none	236474	none
Fexofenadine hydrochloride	histamine	17	16	false	none	This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		87636	none	236474	none
Fexofenadine hydrochloride	erythromycin	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		87636	none	236474	none
Fexofenadine hydrochloride	erythromycin	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		87636	none	236474	none
Fexofenadine hydrochloride	erythromycin	6	4	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
Fexofenadine hydrochloride	erythromycin	6	4	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
Fexofenadine hydrochloride	erythromycin	6	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
Fexofenadine hydrochloride	erythromycin	6	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
Fexofenadine hydrochloride	erythromycin	6	7	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	erythromycin	6	7	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	erythromycin	6	8	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	erythromycin	6	8	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	erythromycin	8	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	erythromycin	8	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	erythromycin	8	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	erythromycin	8	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	erythromycin	8	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	erythromycin	8	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
Fexofenadine hydrochloride	erythromycin	8	9	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	erythromycin	8	9	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	erythromycin	9	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	erythromycin	9	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	erythromycin	9	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	erythromycin	9	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	erythromycin	9	9	false	none	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
Fexofenadine hydrochloride	erythromycin	9	9	false	none	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	ketoconazole	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		87636	none	236474	none
fexofenadine hydrochloride	ketoconazole	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		87636	none	236474	none
fexofenadine hydrochloride	ketoconazole	6	4	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
fexofenadine hydrochloride	ketoconazole	6	4	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
fexofenadine hydrochloride	ketoconazole	6	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
fexofenadine hydrochloride	ketoconazole	6	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
fexofenadine hydrochloride	ketoconazole	6	7	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	ketoconazole	6	7	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	ketoconazole	6	8	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	ketoconazole	6	8	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	ketoconazole	8	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	ketoconazole	8	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	ketoconazole	8	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	ketoconazole	8	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	ketoconazole	8	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	ketoconazole	8	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	ketoconazole	8	9	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	ketoconazole	8	9	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	ketoconazole	9	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	ketoconazole	9	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	ketoconazole	9	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	ketoconazole	9	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	ketoconazole	9	9	false	none	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	ketoconazole	9	9	false	none	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	17	15	false	none	7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	17	15	false	none	7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	17	17	false	none	The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	17	17	false	none	The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	1	1	false	none	7 DRUG INTERACTIONS    7.1 Antacids    Fexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids.  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	1	1	false	none	7 DRUG INTERACTIONS    7.1 Antacids    Fexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids.  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	1	2	false	none	7 DRUG INTERACTIONS    7.1 Antacids    Fexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids.  In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	1	2	false	none	7 DRUG INTERACTIONS    7.1 Antacids    Fexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids.  In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	2	1	false	none	7 DRUG INTERACTIONS    7.1 Antacids    Fexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids.  In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	2	1	false	none	7 DRUG INTERACTIONS    7.1 Antacids    Fexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids.  In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	2	2	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	2	2	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	21	21	false	none	Therefore, to maximize the effects of fexofenadine, it is recommended that fexofenadine hydrochloride tablets should be taken with water [see Clinical Pharmacology (12.3) and Dosage and Administration (2.1)].  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	21	21	false	none	Therefore, to maximize the effects of fexofenadine, it is recommended that fexofenadine hydrochloride tablets should be taken with water [see Clinical Pharmacology (12.3) and Dosage and Administration (2.1)].  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	21	20	false	none	In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%.  Therefore, to maximize the effects of fexofenadine, it is recommended that fexofenadine hydrochloride tablets should be taken with water [see Clinical Pharmacology (12.3) and Dosage and Administration (2.1)].  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	21	20	false	none	In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%.  Therefore, to maximize the effects of fexofenadine, it is recommended that fexofenadine hydrochloride tablets should be taken with water [see Clinical Pharmacology (12.3) and Dosage and Administration (2.1)].  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	6	4	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	6	4	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	6	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	6	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	6	7	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	6	7	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	6	8	true	negative	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	6	8	true	negative	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	8	6	true	negative	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	8	6	true	negative	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	8	7	true	negative	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	8	7	true	negative	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	8	8	true	negative	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	8	8	true	negative	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	8	9	true	negative	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	8	9	true	negative	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	9	7	true	negative	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	9	7	true	negative	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	9	8	true	negative	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	9	8	true	negative	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	9	9	false	none	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	Fexofenadine	9	9	false	none	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	Maalox	1	2	false	none	7 DRUG INTERACTIONS    7.1 Antacids    Fexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids.  In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  		87636	none	236474	none
fexofenadine hydrochloride	Maalox	1	2	false	none	7 DRUG INTERACTIONS    7.1 Antacids    Fexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids.  In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  		87636	none	236474	none
fexofenadine hydrochloride	Maalox	1	3	false	none	7 DRUG INTERACTIONS    7.1 Antacids    Fexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids.  In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  		87636	none	236474	none
fexofenadine hydrochloride	Maalox	1	3	false	none	7 DRUG INTERACTIONS    7.1 Antacids    Fexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids.  In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  		87636	none	236474	none
fexofenadine hydrochloride	Maalox	2	2	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  		87636	none	236474	none
fexofenadine hydrochloride	Maalox	2	2	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  		87636	none	236474	none
fexofenadine hydrochloride	Maalox	2	3	false	none	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  		87636	none	236474	none
fexofenadine hydrochloride	Maalox	2	3	false	none	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  		87636	none	236474	none
fexofenadine hydrochloride	grapefruit	17	17	false	none	The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		87636	none	236474	none
fexofenadine hydrochloride	grapefruit	17	17	false	none	The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		87636	none	236474	none
fexofenadine hydrochloride	grapefruit	17	15	false	none	7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		87636	none	236474	none
fexofenadine hydrochloride	grapefruit	17	15	false	none	7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		87636	none	236474	none
fexofenadine hydrochloride	grapefruit	21	20	false	none	In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%.  Therefore, to maximize the effects of fexofenadine, it is recommended that fexofenadine hydrochloride tablets should be taken with water [see Clinical Pharmacology (12.3) and Dosage and Administration (2.1)].  		87636	none	236474	none
fexofenadine hydrochloride	grapefruit	21	20	false	none	In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%.  Therefore, to maximize the effects of fexofenadine, it is recommended that fexofenadine hydrochloride tablets should be taken with water [see Clinical Pharmacology (12.3) and Dosage and Administration (2.1)].  		87636	none	236474	none
fexofenadine hydrochloride	Erythromycin	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		87636	none	236474	none
fexofenadine hydrochloride	Erythromycin	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		87636	none	236474	none
fexofenadine hydrochloride	Erythromycin	6	4	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
fexofenadine hydrochloride	Erythromycin	6	4	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
fexofenadine hydrochloride	Erythromycin	6	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
fexofenadine hydrochloride	Erythromycin	6	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
fexofenadine hydrochloride	Erythromycin	6	7	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	Erythromycin	6	7	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	Erythromycin	6	8	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	Erythromycin	6	8	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	Erythromycin	8	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	Erythromycin	8	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	Erythromycin	8	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	Erythromycin	8	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	Erythromycin	8	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	Erythromycin	8	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	Erythromycin	8	9	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	Erythromycin	8	9	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	Erythromycin	9	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	Erythromycin	9	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	Erythromycin	9	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	Erythromycin	9	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	Erythromycin	9	9	false	none	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	Erythromycin	9	9	false	none	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	Ketoconazole	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		87636	none	236474	none
fexofenadine hydrochloride	Ketoconazole	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		87636	none	236474	none
fexofenadine hydrochloride	Ketoconazole	6	4	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
fexofenadine hydrochloride	Ketoconazole	6	4	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
fexofenadine hydrochloride	Ketoconazole	6	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
fexofenadine hydrochloride	Ketoconazole	6	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
fexofenadine hydrochloride	Ketoconazole	6	7	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	Ketoconazole	6	7	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	Ketoconazole	6	8	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	Ketoconazole	6	8	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	Ketoconazole	8	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	Ketoconazole	8	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	Ketoconazole	8	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	Ketoconazole	8	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	Ketoconazole	8	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	Ketoconazole	8	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	Ketoconazole	8	9	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	Ketoconazole	8	9	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	Ketoconazole	9	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	Ketoconazole	9	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	Ketoconazole	9	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	Ketoconazole	9	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	Ketoconazole	9	9	false	none	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	Ketoconazole	9	9	false	none	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	orange	17	17	false	none	The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		87636	none	236474	none
fexofenadine hydrochloride	orange	17	17	false	none	The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		87636	none	236474	none
fexofenadine hydrochloride	orange	17	15	false	none	7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		87636	none	236474	none
fexofenadine hydrochloride	orange	17	15	false	none	7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		87636	none	236474	none
fexofenadine hydrochloride	orange	21	20	false	none	In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%.  Therefore, to maximize the effects of fexofenadine, it is recommended that fexofenadine hydrochloride tablets should be taken with water [see Clinical Pharmacology (12.3) and Dosage and Administration (2.1)].  		87636	none	236474	none
fexofenadine hydrochloride	orange	21	20	false	none	In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%.  Therefore, to maximize the effects of fexofenadine, it is recommended that fexofenadine hydrochloride tablets should be taken with water [see Clinical Pharmacology (12.3) and Dosage and Administration (2.1)].  		87636	none	236474	none
fexofenadine hydrochloride	histamine	17	16	false	none	This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		87636	none	236474	none
fexofenadine hydrochloride	histamine	17	16	false	none	This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		87636	none	236474	none
fexofenadine hydrochloride	erythromycin	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		87636	none	236474	none
fexofenadine hydrochloride	erythromycin	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		87636	none	236474	none
fexofenadine hydrochloride	erythromycin	6	4	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
fexofenadine hydrochloride	erythromycin	6	4	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
fexofenadine hydrochloride	erythromycin	6	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
fexofenadine hydrochloride	erythromycin	6	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		87636	none	236474	none
fexofenadine hydrochloride	erythromycin	6	7	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	erythromycin	6	7	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	erythromycin	6	8	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	erythromycin	6	8	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	erythromycin	8	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	erythromycin	8	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	erythromycin	8	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	erythromycin	8	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	erythromycin	8	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	erythromycin	8	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		87636	none	236474	none
fexofenadine hydrochloride	erythromycin	8	9	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	erythromycin	8	9	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	erythromycin	9	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	erythromycin	9	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	erythromycin	9	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	erythromycin	9	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	erythromycin	9	9	false	none	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
fexofenadine hydrochloride	erythromycin	9	9	false	none	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		87636	none	236474	none
ketoconazole	Fexofenadine	4	2	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		none	none	none	none
ketoconazole	Fexofenadine	4	4	false	none	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		none	none	none	none
ketoconazole	Fexofenadine	4	6	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
ketoconazole	Fexofenadine	6	4	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
ketoconazole	Fexofenadine	6	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
ketoconazole	Fexofenadine	6	7	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
ketoconazole	Fexofenadine	6	8	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
ketoconazole	Fexofenadine	7	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
ketoconazole	Fexofenadine	7	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
ketoconazole	Fexofenadine	7	8	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
ketoconazole	Fexofenadine	7	9	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
ketoconazole	Fexofenadine	8	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
ketoconazole	Fexofenadine	8	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
ketoconazole	Fexofenadine	8	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
ketoconazole	Fexofenadine	8	9	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
ketoconazole	Fexofenadine	9	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
ketoconazole	Fexofenadine	9	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
ketoconazole	Fexofenadine	9	9	false	none	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
ketoconazole	Fexofenadine	12	12	true	positive	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  		none	none	none	none
ketoconazole	Fexofenadine	12	13	true	positive	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  		none	none	none	none
ketoconazole	Fexofenadine	12	14	true	positive	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
ketoconazole	Fexofenadine	14	12	true	positive	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
ketoconazole	Fexofenadine	14	13	true	positive	This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
ketoconazole	Fexofenadine	14	14	true	positive	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
ketoconazole	Fexofenadine	14	15	true	positive	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  		none	none	none	none
ketoconazole	Maalox	4	2	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		none	none	none	none
ketoconazole	Maalox	4	3	false	none	1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		none	none	none	none
ketoconazole	grapefruit	14	15	false	none	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  		none	none	none	none
ketoconazole	Erythromycin	4	4	false	none	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		none	none	none	none
ketoconazole	Erythromycin	4	6	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
ketoconazole	Erythromycin	6	4	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
ketoconazole	Erythromycin	6	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
ketoconazole	Erythromycin	6	7	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
ketoconazole	Erythromycin	6	8	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
ketoconazole	Erythromycin	7	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
ketoconazole	Erythromycin	7	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
ketoconazole	Erythromycin	7	8	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
ketoconazole	Erythromycin	7	9	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
ketoconazole	Erythromycin	8	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
ketoconazole	Erythromycin	8	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
ketoconazole	Erythromycin	8	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
ketoconazole	Erythromycin	8	9	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
ketoconazole	Erythromycin	9	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
ketoconazole	Erythromycin	9	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
ketoconazole	Erythromycin	9	9	false	none	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
ketoconazole	Erythromycin	12	12	false	none	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  		none	none	none	none
ketoconazole	Erythromycin	12	14	false	none	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
ketoconazole	Erythromycin	14	12	false	none	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
ketoconazole	Erythromycin	14	14	false	none	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
ketoconazole	orange	14	15	false	none	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  		none	none	none	none
ketoconazole	histamine	14	16	false	none	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  		none	none	none	none
ketoconazole	erythromycin	4	4	false	none	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		none	none	none	none
ketoconazole	erythromycin	4	6	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
ketoconazole	erythromycin	6	4	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
ketoconazole	erythromycin	6	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
ketoconazole	erythromycin	6	7	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
ketoconazole	erythromycin	6	8	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
ketoconazole	erythromycin	7	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
ketoconazole	erythromycin	7	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
ketoconazole	erythromycin	7	8	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
ketoconazole	erythromycin	7	9	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
ketoconazole	erythromycin	8	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
ketoconazole	erythromycin	8	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
ketoconazole	erythromycin	8	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
ketoconazole	erythromycin	8	9	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
ketoconazole	erythromycin	9	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
ketoconazole	erythromycin	9	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
ketoconazole	erythromycin	9	9	false	none	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
ketoconazole	erythromycin	12	12	false	none	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  		none	none	none	none
ketoconazole	erythromycin	12	14	false	none	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
ketoconazole	erythromycin	14	12	false	none	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
ketoconazole	erythromycin	14	14	false	none	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
Fexofenadine	Maalox	1	2	false	none	7 DRUG INTERACTIONS    7.1 Antacids    Fexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids.  In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  		none	none	none	none
Fexofenadine	Maalox	1	3	false	none	7 DRUG INTERACTIONS    7.1 Antacids    Fexofenadine hydrochloride should not be taken closely in time with aluminum and magnesium containing antacids.  In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  		none	none	none	none
Fexofenadine	Maalox	2	2	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  		none	none	none	none
Fexofenadine	Maalox	2	3	false	none	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  		none	none	none	none
Fexofenadine	Maalox	4	2	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		none	none	none	none
Fexofenadine	Maalox	4	3	false	none	1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		none	none	none	none
Fexofenadine	grapefruit	13	15	false	none	This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  		none	none	none	none
Fexofenadine	grapefruit	14	15	false	none	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  		none	none	none	none
Fexofenadine	grapefruit	15	17	false	none	7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		none	none	none	none
Fexofenadine	grapefruit	15	15	false	none	7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  		none	none	none	none
Fexofenadine	grapefruit	17	17	false	none	The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		none	none	none	none
Fexofenadine	grapefruit	17	15	false	none	7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		none	none	none	none
Fexofenadine	grapefruit	21	20	false	none	In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%.  Therefore, to maximize the effects of fexofenadine, it is recommended that fexofenadine hydrochloride tablets should be taken with water [see Clinical Pharmacology (12.3) and Dosage and Administration (2.1)].  		none	none	none	none
Fexofenadine	grapefruit	20	20	false	none	In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%.  		none	none	none	none
Fexofenadine	Erythromycin	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		none	none	none	none
Fexofenadine	Erythromycin	4	4	false	none	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		none	none	none	none
Fexofenadine	Erythromycin	4	6	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
Fexofenadine	Erythromycin	6	4	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
Fexofenadine	Erythromycin	6	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
Fexofenadine	Erythromycin	6	7	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
Fexofenadine	Erythromycin	6	8	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
Fexofenadine	Erythromycin	7	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
Fexofenadine	Erythromycin	7	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
Fexofenadine	Erythromycin	7	8	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
Fexofenadine	Erythromycin	7	9	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
Fexofenadine	Erythromycin	8	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
Fexofenadine	Erythromycin	8	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
Fexofenadine	Erythromycin	8	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
Fexofenadine	Erythromycin	8	9	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
Fexofenadine	Erythromycin	9	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
Fexofenadine	Erythromycin	9	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
Fexofenadine	Erythromycin	9	9	false	none	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
Fexofenadine	Erythromycin	12	12	true	positive	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  		none	none	none	none
Fexofenadine	Erythromycin	12	14	true	positive	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
Fexofenadine	Erythromycin	13	12	true	positive	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  		none	none	none	none
Fexofenadine	Erythromycin	13	14	true	positive	This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
Fexofenadine	Erythromycin	14	12	true	positive	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
Fexofenadine	Erythromycin	14	14	true	positive	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
Fexofenadine	Erythromycin	15	14	true	positive	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  		none	none	none	none
Fexofenadine	Ketoconazole	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		none	none	none	none
Fexofenadine	Ketoconazole	4	4	false	none	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		none	none	none	none
Fexofenadine	Ketoconazole	4	6	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
Fexofenadine	Ketoconazole	6	4	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
Fexofenadine	Ketoconazole	6	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
Fexofenadine	Ketoconazole	6	7	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
Fexofenadine	Ketoconazole	6	8	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
Fexofenadine	Ketoconazole	7	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
Fexofenadine	Ketoconazole	7	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
Fexofenadine	Ketoconazole	7	8	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
Fexofenadine	Ketoconazole	7	9	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
Fexofenadine	Ketoconazole	8	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
Fexofenadine	Ketoconazole	8	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
Fexofenadine	Ketoconazole	8	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
Fexofenadine	Ketoconazole	8	9	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
Fexofenadine	Ketoconazole	9	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
Fexofenadine	Ketoconazole	9	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
Fexofenadine	Ketoconazole	9	9	false	none	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
Fexofenadine	Ketoconazole	12	12	true	positive	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  		none	none	none	none
Fexofenadine	Ketoconazole	12	14	true	positive	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
Fexofenadine	Ketoconazole	13	12	true	positive	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  		none	none	none	none
Fexofenadine	Ketoconazole	13	14	true	positive	This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
Fexofenadine	Ketoconazole	14	12	true	positive	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
Fexofenadine	Ketoconazole	14	14	true	positive	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
Fexofenadine	Ketoconazole	15	14	true	positive	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  		none	none	none	none
Fexofenadine	orange	13	15	false	none	This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  		none	none	none	none
Fexofenadine	orange	14	15	false	none	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  		none	none	none	none
Fexofenadine	orange	15	17	false	none	7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		none	none	none	none
Fexofenadine	orange	15	15	false	none	7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  		none	none	none	none
Fexofenadine	orange	17	17	false	none	The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		none	none	none	none
Fexofenadine	orange	17	15	false	none	7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		none	none	none	none
Fexofenadine	orange	21	20	false	none	In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%.  Therefore, to maximize the effects of fexofenadine, it is recommended that fexofenadine hydrochloride tablets should be taken with water [see Clinical Pharmacology (12.3) and Dosage and Administration (2.1)].  		none	none	none	none
Fexofenadine	orange	20	20	false	none	In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%.  		none	none	none	none
Fexofenadine	histamine	14	16	false	none	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  		none	none	none	none
Fexofenadine	histamine	15	16	false	none	7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  		none	none	none	none
Fexofenadine	histamine	17	16	false	none	This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		none	none	none	none
Fexofenadine	erythromycin	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		none	none	none	none
Fexofenadine	erythromycin	4	4	false	none	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		none	none	none	none
Fexofenadine	erythromycin	4	6	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
Fexofenadine	erythromycin	6	4	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
Fexofenadine	erythromycin	6	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
Fexofenadine	erythromycin	6	7	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
Fexofenadine	erythromycin	6	8	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
Fexofenadine	erythromycin	7	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
Fexofenadine	erythromycin	7	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
Fexofenadine	erythromycin	7	8	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
Fexofenadine	erythromycin	7	9	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
Fexofenadine	erythromycin	8	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
Fexofenadine	erythromycin	8	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
Fexofenadine	erythromycin	8	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
Fexofenadine	erythromycin	8	9	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
Fexofenadine	erythromycin	9	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
Fexofenadine	erythromycin	9	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
Fexofenadine	erythromycin	9	9	false	none	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
Fexofenadine	erythromycin	12	12	true	positive	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  		none	none	none	none
Fexofenadine	erythromycin	12	14	true	positive	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
Fexofenadine	erythromycin	13	12	true	positive	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  		none	none	none	none
Fexofenadine	erythromycin	13	14	true	positive	This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
Fexofenadine	erythromycin	14	12	true	positive	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
Fexofenadine	erythromycin	14	14	true	positive	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
Fexofenadine	erythromycin	15	14	true	positive	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  		none	none	none	none
Maalox	Erythromycin	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		none	none	none	none
Maalox	Erythromycin	3	4	false	none	1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		none	none	none	none
Maalox	Ketoconazole	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		none	none	none	none
Maalox	Ketoconazole	3	4	false	none	1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		none	none	none	none
Maalox	erythromycin	2	4	true	positive	In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.  1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		none	none	none	none
Maalox	erythromycin	3	4	false	none	1 Maalox® is a registered trademark of Novartis Consumer Healthcare.  7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		none	none	none	none
grapefruit	Erythromycin	15	14	false	none	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  		none	none	none	none
grapefruit	Ketoconazole	15	14	false	none	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  		none	none	none	none
grapefruit	orange	17	17	false	none	The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		none	none	none	none
grapefruit	orange	17	15	false	none	7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		none	none	none	none
grapefruit	orange	20	20	false	none	In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of fexofenadine was reduced by 36%.  		none	none	none	none
grapefruit	orange	15	17	false	none	7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		none	none	none	none
grapefruit	orange	15	15	false	none	7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  		none	none	none	none
grapefruit	histamine	17	16	false	none	This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		none	none	none	none
grapefruit	histamine	15	16	false	none	7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  		none	none	none	none
grapefruit	erythromycin	15	14	false	none	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  		none	none	none	none
Erythromycin	Ketoconazole	4	4	false	none	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		none	none	none	none
Erythromycin	Ketoconazole	4	6	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
Erythromycin	Ketoconazole	6	4	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
Erythromycin	Ketoconazole	6	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
Erythromycin	Ketoconazole	6	7	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
Erythromycin	Ketoconazole	6	8	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
Erythromycin	Ketoconazole	7	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
Erythromycin	Ketoconazole	7	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
Erythromycin	Ketoconazole	7	8	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
Erythromycin	Ketoconazole	7	9	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
Erythromycin	Ketoconazole	8	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
Erythromycin	Ketoconazole	8	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
Erythromycin	Ketoconazole	8	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
Erythromycin	Ketoconazole	8	9	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
Erythromycin	Ketoconazole	9	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
Erythromycin	Ketoconazole	9	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
Erythromycin	Ketoconazole	9	9	false	none	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
Erythromycin	Ketoconazole	12	12	false	none	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  		none	none	none	none
Erythromycin	Ketoconazole	12	14	false	none	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
Erythromycin	Ketoconazole	14	12	false	none	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
Erythromycin	Ketoconazole	14	14	false	none	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
Erythromycin	orange	14	15	false	none	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  		none	none	none	none
Erythromycin	histamine	14	16	false	none	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  		none	none	none	none
Ketoconazole	orange	14	15	false	none	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  		none	none	none	none
Ketoconazole	histamine	14	16	false	none	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  		none	none	none	none
Ketoconazole	erythromycin	4	4	false	none	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  		none	none	none	none
Ketoconazole	erythromycin	4	6	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
Ketoconazole	erythromycin	6	4	true	positive	7.2 Erythromycin and Ketoconazole    Fexofenadine has been shown to exhibit minimal (ca.  5%) metabolism.  However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
Ketoconazole	erythromycin	6	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  		none	none	none	none
Ketoconazole	erythromycin	6	7	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
Ketoconazole	erythromycin	6	8	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
Ketoconazole	erythromycin	7	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
Ketoconazole	erythromycin	7	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  		none	none	none	none
Ketoconazole	erythromycin	7	8	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
Ketoconazole	erythromycin	7	9	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
Ketoconazole	erythromycin	8	6	false	none	However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects.  Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
Ketoconazole	erythromycin	8	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
Ketoconazole	erythromycin	8	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  		none	none	none	none
Ketoconazole	erythromycin	8	9	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
Ketoconazole	erythromycin	9	7	false	none	Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole.  In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
Ketoconazole	erythromycin	9	8	false	none	In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study).  No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
Ketoconazole	erythromycin	9	9	false	none	No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either erythromycin or ketoconazole.  		none	none	none	none
Ketoconazole	erythromycin	12	12	false	none	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  		none	none	none	none
Ketoconazole	erythromycin	12	14	false	none	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
Ketoconazole	erythromycin	14	12	false	none	These studies indicate that ketoconazole or erythromycin coadministration enhances fexofenadine gastrointestinal absorption.  This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein.  In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
Ketoconazole	erythromycin	14	14	false	none	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  		none	none	none	none
orange	histamine	17	16	false	none	This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administered with either grapefruit or orange juices compared to water.  		none	none	none	none
orange	histamine	15	16	false	none	7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  		none	none	none	none
orange	erythromycin	15	14	false	none	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  		none	none	none	none
histamine	erythromycin	16	14	false	none	In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.  7.3 Fruit Juices    Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of fexofenadine.  This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis.  		none	none	none	none
